Biocon has reported results for fourth quarter (Q4) and year ended March 31, 2023.
The company has reported many fold jump in net profit at Rs 1810.80 crore for the quarter under review as compared to Rs 38.10 crore for the same quarter in the previous year. However, total income of the company decreased by 1.35% at Rs 570.70 crore for Q4FY23 as compared to Rs 578.50 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 46% rise in its net profit at Rs 414.50 crore for fourth quarter ended March 31, 2023 as compared to Rs 283.90 crore for the same quarter in the previous year. Total income of the company increased by 58.67% at Rs 3928.80 crore for Q4FY23 as compared to Rs 2476.10 crore for the corresponding quarter previous year.
For the year ended March 31, 2023, the company has reported many fold jump in its net profit at Rs 2848.40 crore as compared to Rs 86.10 crore for the previous year. Total income of the company increased by 17.60% at Rs 2264.30 crore for year under review as compared to Rs 1925.40 crore for year ended March 31, 2022.
For the year ended March 31, 2023, on the consolidated basis, the company has reported 16.67% fall in its net profit at Rs 643.00 crore as compared to Rs 771.60 crore for the previous year. However, total income of the company increased by 37.56% at Rs 11550.10 crore for year under review as compared to Rs 8396.70 crore for year ended March 31, 2022.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1849.05 |
Dr. Reddys Lab | 1274.25 |
Cipla | 1553.20 |
Lupin | 2184.00 |
Zydus Lifesciences | 1001.85 |
View more.. |